Treatment of feline intermediate‐ to high‐grade lymphoma with a modified university of Wisconsin–Madison protocol: 119 cases (2004–2012)

Collette, Sandra; Allstadt, Sara D.; Chon, Esther; Vernau, William; Smith, Annette; Garrett, Laura D.; Choy, Kevin; Rebhun, Robert B.; Rodríguez, C. O.; Skorupski, Katherine A

doi:10.1111/vco.12158

Cited by 60 publications

(132 citation statements)

References 35 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…There is also a dichotomy in cases of feline LSA, with potentially greater than half of cats lacking significant response to chemotherapy and only a small subset of cats entering a durable clinical remission. Cats that are nonresponsive to chemotherapy have short MST ranging from 27 to 73 days, which is less than or statistically equal to the MST in this study.…”

Section: Discussioncontrasting

confidence: 82%

“…The overall survival times in this study are comparable to those reported for cats with GI LSA treated with systemic chemotherapy alone . In addition to improving survival time, maintaining quality of life is an important goal in LSA case management because treatment is often palliative in nature.…”

Section: Discussionsupporting

confidence: 71%

“…Most often, this treatment consists of COP (cyclophosphamide, vincristine, prednisolone) or CHOP (plus doxorubicin)‐based protocols. Unlike in dogs, in which multicentric LSA predominates and is overwhelmingly responsive to chemotherapy, the response to multiagent chemotherapy in cats with feline GI large‐cell LSA is less predictable, with overall response rates ranging from 30% to 75% . Response durability also tends to be less favorable, with reported median survival times (MST) of 3 to 6 months .…”

Section: Introductionmentioning

confidence: 99%

“…Unlike in dogs, in which multicentric LSA predominates and is overwhelmingly responsive to chemotherapy, the response to multiagent chemotherapy in cats with feline GI large-cell LSA is less predictable, with overall response rates ranging from 30% to 75%. [4][5][6][7][8][9][10][11] Response durability also tends to be less favorable, with reported median survival times (MST) of 3 to 6 months. 1,[4][5][6][7][8][9][10][11][12] However, MST tends to be closely linked to response to chemotherapy.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Outcomes in 40 cats with discrete intermediate‐ or large‐cell gastrointestinal lymphoma masses treated with surgical mass resection (2005‐2015)

et al. 2019

View full text Add to dashboard Cite

Objective To report outcomes in cats with discrete intermediate‐ and large‐cell gastrointestinal (GI) lymphoma masses after surgical resection. Study design Retrospective clinical case series. Animals Forty client‐owned cats in which intermediate‐ or large‐cell GI lymphoma was diagnosed. Methods Records of 40 cats in which discrete intermediate‐ or large‐cell GI lymphoma masses were diagnosed between 2005 and 2015 were reviewed. Cats were included if they survived curative intent surgery and had a known outcome for at least two weeks. Postoperative death was permitted. Data collected included anatomic site, surgical margins, lymphoma subtype, chemotherapy use, and postoperative and long‐term outcome (beyond two weeks). Results Affected sites consisted of small intestines (n = 23), large intestines (n = 9), and stomach (n = 8). Thirty‐six of 40 cats survived to discharge, and 31 cats were alive at suture removal. Median long‐term follow‐up of 22 cats was 111 days (range, 16‐1407). Cats that survived to suture removal had a median survival time (MST) of 185 days (95% confidence interval: 72‐465). Cats with large intestinal masses lived longer than those with small intestinal or gastric masses whether all cats (MST, 675, 64, 96 days, respectively; P = .03) or only those surviving to suture removal were considered. Complete surgical resection (n = 20) was positively associated with survival (370 vs 83 days, P = .016). Conclusion Most cats in this population survived the perioperative period, with MST similar to those reported historically with medical management. Clinical significance Surgical resection may be a reasonable consideration in cats with solitary lymphoma, particularly those with large intestinal masses.

show abstract

Section: Discussioncontrasting

confidence: 82%

Section: Discussionsupporting

confidence: 71%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Outcomes in 40 cats with discrete intermediate‐ or large‐cell gastrointestinal lymphoma masses treated with surgical mass resection (2005‐2015)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Safety and efficacy of cyclophosphamide and vincristine administered IP to 26 cats with various forms of malignant lymphoma have been confirmed. 7 No specific IP-related adverse effects were seen in any cats of that study, 7 and cats had similar survival times after administration via that route, compared with survival times for other reports, 4–6,13 which indicated probable efficacy. A pharmacokinetic analysis revealed equal bioavailability of the parent compound (cyclophosphamide) given IV or IP; however, the active metabolite 4-OHCP was not measured.…”

supporting

confidence: 48%

Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide

Stroda¹,

Murphy²,

Hansen³

et al. 2017

ajvr

View full text Add to dashboard Cite

OBJECTIVE To characterize pharmacokinetics of cyclophosphamide and 4-hydoxycyclophosphamide (4-OHCP) in the plasma of healthy cats after oral, intravenously, or intraperitoneal administration of cyclophosphamide. ANIMALS 6 healthy adult cats. PROCEDURES Cats were randomly assigned to receive 200 mg/m2 of cyclophosphamide via each of 3 routes of administration (oral, IV, and IP); there was a 30-day washout period between successive treatments. Plasma samples were obtained at various time points for up to 8 hours after administration. Samples were treated with semicarbazide hydrochloride to trap the 4-OHCP in stable form, which allowed for cyclophosphamide and trapped 4-OHCP to be simultaneously measured by use of tandem mass spectrometry. Pharmacokinetic parameters were determined from drug concentration–versus-time data for both cyclophosphamide and 4-OHCP. RESULTS Cyclophosphamide was tolerated well regardless of route of administration. Pharmacokinetic parameters for 4-OHCP were similar after oral, IV, and IP administration. Area under the concentration-time curve for cyclophosphamide was lower after oral administration than after IV or IP administration. CONCLUSIONS AND CLINICAL RELEVANCE Cyclophosphamide can be administered interchangeably to cats as oral, IV, and IP, formulations, which should provide benefits with regard to cost and ease of administration to certain feline patients. (Am J Vet Res 2017;78:862–866)

show abstract

Multi‐modal Therapy

Banks¹,

Mullin²,

Clifford³

2022

Veterinary Surgical Oncology

View full text Add to dashboard Cite

Treatment of feline intermediate‐ to high‐grade lymphoma with a modified university of Wisconsin–Madison protocol: 119 cases (2004–2012)

Cited by 60 publications

References 35 publications

Outcomes in 40 cats with discrete intermediate‐ or large‐cell gastrointestinal lymphoma masses treated with surgical mass resection (2005‐2015)

Outcomes in 40 cats with discrete intermediate‐ or large‐cell gastrointestinal lymphoma masses treated with surgical mass resection (2005‐2015)

Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide

Multi‐modal Therapy

Contact Info

Product

Resources

About